Loading clinical trials...
Loading clinical trials...
An Open-Label Treatment Use Protocol for Daratumumab in Subjects With Multiple Myeloma Who Have Received at Least 3 Prior Lines of Therapy (Including a Proteasome Inhibitor and an Immunomodulatory Agent) or Are Double Refractory to a Proteasome Inhibitor and an Immunomodulatory Agent
Conditions
Interventions
Daratumumab
Locations
79
United States
Phoenix, Arizona, United States
Little Rock, Arkansas, United States
Duarte, California, United States
Fountain Valley, California, United States
Gilroy, California, United States
Greenbrae, California, United States
Last Updated
January 15, 2019
NCT06179888
NCT06152575
NCT04973605
NCT05201781
NCT05862012
NCT06138275
Lead Sponsor
Janssen Research & Development, LLC
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions